Showing results (41-50 of 566) with videos related to
Sort By:
Pageof 57
Cancer Research|May 15, 1990
Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in miceA Engert, G Martin, M Pfreundschuh, et al.Journal of Immunological Methods|July 12, 1994
Differentiation of cytotoxicity using target cells labelled with europium and samarium by electroporationH Bohlen, O Manzke, A Engert, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1996
Interleukin 10 inhibits cytokine production of human AML cellsF Westermann, D Kube, B Haier, et al.Annals of Hematology|March 24, 1999
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemiaK Hübel, K Hegener, R Schnell, et al.Leukemia|April 14, 2000
A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemiaT Pfitzner, A Engert, H Wittor, et al.Leukemia & Lymphoma|July 16, 2005
Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's diseaseL Smardova, A Engert, H Haverkamp, et al.Blood|June 14, 2000
Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID miceS Barth, M Huhn, B Matthey, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2001
Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosisU Rueffer, A Josting, J Franklin, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 1998
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM)A Josting, I Kàtay, U Rueffer, et al.Blood|September 15, 1993
Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodiesH Bohlen, T Hopff, O Manzke, et al.Pageof 57